Chronic Kidney Disease

High consumption of sugary beverages has previously been linked to obesity, diabetes, and some types of cancer.

A multimethod approach including use of refill data may be the most effective method to identify nonadherence in young patients with chronic kidney disease.

In an additional analysis from the CANVAS program, new data reinforce evidence of improved renal outcomes for those with type 2 diabetes and chronic kidney disease.

Screening for HBV among high-risk populations is crucial to stopping transmission of the virus.

HIV-positive patients need to maintain healthy body weight, quit smoking, eat well, exercise regularly and treat hypertension, diabetes and dyslipidemia.

Direct-acting antivirals drugs show similar cure rates in co-infected patients as high as mono-infected patients.

Heplisav-B is the only 2-dose hepatitis B vaccine recombinant approved in the United States.

Ferric citrate was originally approved for the control of serum phosphorus levels in patients with chronic kidney disease who require dialysis.

An aspirin a day may reduce their risk of hepatocellular carcinoma in patients with hepatitis B virus.

Patients with chronic kidney disease are at risk for several comorbid conditions, including cardiovascular disease.

Patients who develop chronic kidney disease (CKD) are at risk for a number of comorbidities, including cardiovascular decline.

Women with the hepatitis C virus have fewer live births and face a higher risk of miscarriage, infertility, gestational diabetes and pre-eclampsia.

Patients with stage 3 kidney disease cured of hepatitis C virus experienced an improvement in kidney function following treatment.

Sofosbuvir may help improve the kidney function of some patients with hepatitis C virus.

Results from the EMPA-REG OUTCOME trial suggests empagliflozin (Jardiance) has potential in the treatment of chronic kidney disease.

Epoetin alfa biosimilar has indications in cancer, HIV, and chronic kidney disease, among other conditions.

This is the first recommendation for a proposed erythropoiesis-stimulating agent biosimilar.

Top news of the day from across the health care landscape.

More than half of patients taking proton pump inhibitors experienced sudden onset of chronic kidney disease.

Parsabiv is the first hyperparathyroidism drug to be approved in more than 10 years.

Oral ferric citrate may affectively raise hemoglobin levels in patients with anemia.

Proton pump inhibitors and histamine receptor-2 blockers have damaging effects on the kidneys.

Pharmacokinetics of anticoagulant tecarfarin not compromised by renal function as seen with warfarin.

Pharmacokinetics of tecarfarin were not compromised by renal function like it was with warfarin.

Although it was previously found that kidney disease can cause diabetes, the diseases also have an inverse relationship.

Increased genetic knowledge about non-whites could lead to improved knowledge and treatments.

It's important to take renal function into consideration when dosing renally-eliminated medications.

Patients with chronic kidney disease who had negative thoughts and feelings had worse outcomes.

Alternative sources of protein such as soy and legumes could protect against kidney failure.